

1 **Ultrasmall radical metal organic cage as cascade antioxidant nanozyme for renal**  
2 **injury**

3 Cheng Huang<sup>1†</sup>, Ziyu Liu<sup>2†</sup>, Yucen Deng<sup>1,3†</sup>, Xiaoyan Wang<sup>4†</sup>, Qing Miao<sup>1</sup>, Demei Sun<sup>1</sup>,  
4 Xinyuan Zhu<sup>1</sup>, Jinghui Yang<sup>5\*</sup>, and Youfu Wang<sup>1\*</sup>

5  
6 1 School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University,  
7 Shanghai 200240, China;

8 2 Department of Nephrology, Shanghai Changzheng Hospital, Naval Medical  
9 University, Shanghai 200003, China;

10 3 School of Pharmacy, China Medical University, Shenyang 110122, China;

11 4 Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University,  
12 Shanghai 200240, China;

13 5 Department of Organ Transplantation, Shanghai Changzheng Hospital, Naval  
14 Medical University, Shanghai 200003, China.

15

16 †These authors contributed equally to this work.

17 \* Corresponding author: J. Yang (yjh@smmu.edu.cn), Y. Wang

18 (wyfown@sjtu.edu.cn)

19

20 **Abstract**

21 **Rationale:** As substitutes for natural enzymes, nanozymes offer tunable enzyme-like  
22 activities and remarkable structural stability, making them potential to treat various  
23 diseases, including renal ischemia-reperfusion (I/R) injury. However, the majority of  
24 developed nanozymes suffer from unclear structures and limited activity profiles, which  
25 hinder the study of their structure-activity relationships, catalytic diversity, mass  
26 production, and clinical application.

27 **Methods:** Herein, we introduce an atomically precise and ultrasmall cascade  
28 nanozyme based on a radical-functionalized metal-organic cage (MOC-R). This

29 nanozyme is synthesized through the coordination of radical ligands with copper ions,  
30 resulting in a cuboctahedral structure.

31 **Results:** The MOC-R exhibits cascade antioxidant activities, mimicking the functions  
32 of superoxide dismutase (SOD) and catalase (CAT), owing to the synergism between  
33 the external radicals and internal copper clusters. The MOC-R nanozyme  
34 demonstrates exceptional radical scavenging and anti-inflammatory properties. It  
35 mitigates immune cell infiltration, promotes macrophage polarization towards the M2-  
36 like phenotype, reduces inflammatory cytokine secretion, and suppresses excessive  
37 autophagy and apoptosis.


38 **Conclusions:** This study not only presents an atomically precise cascade nanozyme  
39 but also highlights its promising therapeutic potential for renal I/R injury.

40

41 **Keywords:** metal organic cage, cascade nanozyme, antioxidant, ischemia reperfusion  
42 injury, kidney

43

#### 44 **Graphical Abstract**



45

46

#### 47 **Introduction**

48 Clinically, renal I/R injury is a significant concern in various medical and surgical  
49 settings. This condition commonly occurs during procedures such as partial  
50 nephrectomy, kidney transplantation, and aortic surgery [1]. In these scenarios, the  
51 temporary cessation of blood flow to the kidneys followed by its re-establishment can

52 lead to severe damage, causing acute tubular necrosis. The underlying mechanisms  
53 responsible for renal I/R injury are complex and multifaceted, involving several  
54 interconnected pathways. One of the key factors is the excessive production of  
55 intracellular reactive oxygen species (ROS). Under normal conditions, ROS are  
56 produced in small amounts and play essential roles in cellular signaling and  
57 homeostasis. However, during ischemia, the lack of oxygen leads to mitochondrial  
58 dysfunction, and upon reperfusion, there is a sudden influx of oxygen that triggers an  
59 overproduction of ROS. Given the central role of ROS in this process, the  
60 administration of antioxidants has been explored as a potential therapeutic strategy.  
61 Various studies have demonstrated promising results in experimental models, where  
62 antioxidants effectively mitigated tissue damage and improved renal function. However,  
63 translating these findings into clinical practice has proven challenging. Drugs designed  
64 to scavenge ROS generated during reperfusion often face limitations in efficacy due to  
65 their unsustainable one-time exhausted character and poor accumulation at the injured  
66 site [2,3]. Enzymes, as remarkable biological catalysts, play a crucial role in facilitating  
67 chemical reactions within living organisms. One of the key characteristics of enzymes  
68 is that they remain structurally and chemically unchanged before and after the  
69 reactions they catalyze. This unique property allows enzymes to be reused multiple  
70 times without losing their functionality [4–8].


71 However, natural enzymes possess a level of complexity and instability that  
72 complicates their synthesis, large-scale production, and long-term preservation. The  
73 intricate three-dimensional structures of natural enzymes are highly sensitive to  
74 environmental factors such as temperature, pH levels, and organic solvents. Even  
75 minor changes in these conditions can lead to denaturation, where the enzyme loses  
76 its functional shape and, consequently, its catalytic ability. This sensitivity poses  
77 significant challenges for industrial and clinical applications, particularly when it comes  
78 to maintaining enzyme activity over extended periods or under varying conditions.  
79 Moreover, the difficulty in producing natural enzymes on a large scale and preserving  
80 them effectively has hindered their widespread use in clinical settings. In medical

81 treatments, enzymes are often required to remain stable and active for prolonged  
82 durations, which is not always feasible with natural enzymes due to their inherent  
83 instability. This limitation has spurred the development of artificial enzymes designed  
84 to mimic the functionality of natural enzymes while offering enhanced structural stability  
85 [9,10]. This has driven the need for artificial enzymes that offer the functionality of  
86 natural enzymes and structural stability. Nanozymes, emerging from advancements in  
87 nanoscience, represent a promising class of artificial enzymes [11,12]. They offer  
88 benefits such as structural stability, multifunctionality, low cost, recyclability, and  
89 feasibility for large-scale production [13,14]. After nearly a decade of evolution, various  
90 nanozymes with diverse structures have been developed to alleviate various diseases  
91 and manifested outstanding physiological activities [15–18]. Despite their potential,  
92 several challenges persist: 1) The often ambiguous structures of nanozymes  
93 complicate the study of their structure-activity relationships and their controlled large-  
94 scale preparation, which hinders clinical application; 2) The lack of standardized  
95 protocols for evaluating catalytic activity makes it difficult to compare different  
96 nanozymes; 3) Many nanozymes exhibit limited and monotonic activity, which restricts  
97 their therapeutic efficacy; 4) The biological safety of nanozymes remains uncertain,  
98 posing risks to clinical use [4,7,19–21]. Addressing these issues by developing  
99 nanozymes with well-defined structures, versatile enzyme-like activities, and superior  
100 biocompatibility is critical for advancing their practical applications.

101 To address the challenges associated with nanozymes, we employed a well-defined  
102 nanoobject integrating various active components. The metal-organic cage (MOC)  
103 offers an atomically precise structure, presenting a uniform, discrete, and ultrasmall  
104 nanopolyhedron formed through the coordination of metal ions or clusters with organic  
105 ligands [22–26]. MOCs integrate the advantages of both organic and inorganic  
106 components, offering several key benefits: 1) By modifying the organic linkers and  
107 metal nodes, researchers can tailor MOCs to possess varying nanoscale cavities and  
108 dimensions. This tunability allows for precise control over pore size and surface area,  
109 enhancing their functionality in applications such as catalysis and drug delivery. 2)

110 Direct coordination of metal ions can shorten the spatial distance between catalytic  
111 sites, facilitating improved cascade catalysis. This arrangement promotes efficient  
112 multi-step reactions by ensuring that intermediates are readily accessible to  
113 subsequent active sites. 3) MOCs exhibit a unique cavity structure that enables  
114 reaction molecules to easily enter the cavities and interact with catalytically active sites  
115 from both inside and outside. This accessibility enhances catalytic efficiency and  
116 selectivity [27–29]. Due to these structural features, functionality, and catalytic activity  
117 of metal sites, MOCs have found extensive use in the biomedical field [30,31]. Actually,  
118 we have successfully constructed MOC-based cascade nanozymes recently, such as  
119 heterometallic MOC and oxidized MOC, demonstrating excellent enzymatic activity  
120 [32–34]. However, despite these advantages, the atomic-level structure of these MOCs  
121 remains unclear, complicating detailed structural analysis and understanding of their  
122 active sites. Additionally, while these MOCs exhibit adequate biocompatibility,  
123 concerns remain regarding potential metallic toxicity [35–37].

124 In this study, we synthesized a novel precise and ultras-small radical MOC nanozyme  
125 with cuboctahedral topology and good water solubility, MOC-R, through robust  
126 coordination between copper ions and functional isophthalic acid, incorporating  
127 oligoethylene glycol and 2,2,6,6-tetramethylpiperidin-1-oxyl (TEMPO) [38,39]. The  
128 mechanistic investigations demonstrated that TEMPO and the copper component drive  
129 the mimicry of superoxide dismutase (SOD) [40,41] and catalase (CAT) [42,43]  
130 activities, respectively, resulting in exceptional antioxidant activity due to their  
131 synergistic effects. *In vitro* and *in vivo* experiments revealed that this synergy provides  
132 significant radical scavenging and anti-inflammatory benefits by reducing immune cell  
133 infiltration, promoting macrophage polarization to the M2-like phenotype, limiting  
134 inflammatory cytokine release, and inhibiting excessive autophagy and apoptosis  
135 (Scheme 1). In summary, this atomically precise and ultras-small cascade antioxidant  
136 nanozyme demonstrates exceptional stability, biocompatibility, ROS scavenging  
137 capacity, and anti-inflammatory performance. These properties are expected to  
138 significantly advance structure-activity studies and facilitate clinical translation.



139

140 **Scheme 1.** Schematic illustration of preparation of precise and ultras-small MOC-R  
 141 cascade nanozyme and its application in treating renal I/R injury. Created with  
 142 BioRender.com.

143

## 144 Results and Discussion


### 145 Preparation and Characterization of MOC-R Nanozyme

146 The detailed synthetic procedures and structural characterizations are provided in the  
 147 Figure 1A and supporting information (Scheme S1, and Figures S1-S12). To  
 148 investigate the source of enzyme-like activity, water-soluble MOC lacking radical  
 149 moieties is synthesized from ligand L. Analysis of the <sup>1</sup>H-NMR spectra for L-R and  
 150 MOC-R (Figure S13) revealed that all peaks for MOC-R were broadened and shifted  
 151 to lower fields compared to those of L-R, which indicate the coordination between L-R  
 152 and Cu<sup>2+</sup>, similar to previously reported results [24]. Specifically, two characteristic  
 153 peaks at 8.41 and 6.37 ppm, attributed to the benzene ring in L-R, shifted to 8.65 and  
 154 6.73 ppm in MOC-R. Fourier transform infrared (FT-IR) spectra showed that both  
 155 ligand L and L-R exhibited a carboxylic acid signal at 1700 cm<sup>-1</sup>. This signal  
 156 disappeared in MOC and MOC-R due to coordination effects (Figure 1B). Additionally,  
 157 characteristic signals for TEMPO at 2940 cm<sup>-1</sup> and 1387 cm<sup>-1</sup> appeared in L-R and

158 MOC-R but were absent in L and MOC. These NMR and FT-IR results confirm the  
159 successful coordination between the ligands and  $\text{Cu}^{2+}$  to form MOC and MOC-R.  
160 Typically, coordination between isophthalic acid and copper ions results in the  
161 formation of a cuboctahedral MOC with a stoichiometric  $\text{Cu}_{24}\text{L}_{24}$  composition. Due to  
162 their large molecular weights, size exclusion chromatography (SEC) was employed to  
163 analyze the molecular weight, stability, and polydispersity of the ligands and MOCs.  
164 SEC plots revealed single sharp peaks at approximately 12.90 min for L and 12.42 min  
165 for L-R, and peaks at 11.62 min for MOC and 11.15 min for MOC-R (Figure 1C). The  
166 shorter elution times for MOC and MOC-R likely reflect their larger hydrodynamic  
167 volumes compared to the ligands. The molecular weights of MOC and MOC-R, as  
168 determined from the SEC plots, were 15763 g/mol and 20867 g/mol, respectively,  
169 closely matching the theoretical values of 16084 g/mol and 22189 g/mol. Furthermore,  
170 MOC and MOC-R exhibited narrow polydispersity indices of 1.13 and 1.06,  
171 respectively, indicating high uniformity, homogeneity, and stability. These molecular  
172 weights were also confirmed by matrix-assisted laser desorption ionization time-of-  
173 flight (MALDI-TOF) mass spectrometry (Figure 1D), where peaks at 16084 and 22189  
174 g/mol were observed, consistent with the theoretical values, confirming the formation  
175 of cuboctahedral MOC and MOC-R.

176 Benefiting from the surface OEG moieties, the water solubility of MOC-R is about 2.5  
177 mg/mL. The size and surface charge of MOC-R were determined using dynamic light  
178 scattering (DLS) and zeta potential measurements for subsequent biological  
179 applications. MOC-R exhibited a hydrated particle size of approximately 7.0 nm with a  
180 narrow polydispersity of 0.18 (Figure 1E) and a slightly negative charge of -3.5 mV,  
181 suggesting good biosafety. The DLS results of MOC-R after being dissolved in PBS or  
182 fetal bovine serum (FBS) for one day are consistent with above value, indicating its  
183 structural stability (Figure S14). Atomic force microscopy (AFM) was used to visualize  
184 the morphology and size of MOC-R (Figure 1F). The height of MOC-R was  
185 approximately 4.5 nm, showing high uniformity, which aligns with the theoretical size  
186 of the cuboctahedral MOC and confirms its structural stability, uniformity, and

187 ultrasmall size. Electron paramagnetic resonance (EPR) spectroscopy was employed  
 188 to examine the radical characteristics of L-R and MOC-R (Figure 1G). The EPR  
 189 spectrum of L-R, showing three consistent peaks, was identical to that of unmodified  
 190 TEMPO, indicating that the radical properties were retained. MOC-R also displayed  
 191 intense radical signals, confirming the presence of radical characteristics after the  
 192 formation of MOC-R. The UV-vis spectra of MOC and MOC-R in PBS (0.2 mg/mL)  
 193 show negligible absorption in 500~650 nm, suitable for the further enzyme activity  
 194 evaluation (Figure S15).



195  
 196 **Figure 1.** Preparation and Characterization of MOC-R cascade nanozyme. (A) The  
 197 structures of ligands, MOC, and MOC-R. (B) The FT-IR spectra of ligands, MOC, and  
 198 MOC-R. (C) The SEC profiles of the ligands, MOC, and MOC-R in THF. (D) The  
 199 MALDI-TOF mass spectra of MOC and MOC-R. (E) The DLS plot of MOC-R in PBS.  
 200 (F) The AFM image of MOC-R. Scale bars represent 500 nm. (G) The EPR curves of  
 201 L-R and MOC-R.

202




## 203 **SOD-like and CAT-like Activities of MOC-R Nanozyme**

204 After fully characterizing the MOC-R nanozyme, its atomically precise and ultrasmall  
205 structure and radical features prompted us to explore its enzyme-like activities. Given  
206 that scavenging superoxide anions ( $\cdot\text{O}_2^-$ ) is crucial in anti-ROS cascade reactions and  
207 considering the established activity of the TEMPO, we initially investigated its SOD-  
208 like activity by monitoring  $\cdot\text{O}_2^-$  elimination. Results from nitrotetrazolium blue chloride  
209 (NBT) [44], a redox indicator for detecting  $\cdot\text{O}_2^-$ , demonstrated that MOC-R and its  
210 components exhibited notable SOD-like activity compared to the PBS control group  
211 (Figure 2A). Specifically,  $\text{Cu}(\text{OAc})_2\cdot\text{H}_2\text{O}$ , L-R, and MOC all displayed evident SOD-like  
212 activity, with the radical L-R showing superior performance. Interestingly, the SOD-like  
213 activity of the assembled MOC was significantly higher than that of  $\text{Cu}(\text{OAc})_2\cdot\text{H}_2\text{O}$ ,  
214 likely due to the active species in MOC being the  $\text{Cu}_2(\text{COO}^-)_4$  paddlewheel cluster  
215 rather than free copper ions [45,46]. Notably, the integrated MOC-R exhibited the most  
216 pronounced SOD-like characteristics, indicating that the formation of MOC-R  
217 enhanced its SOD-like activity, primarily due to the TEMPO moieties and assisted by  
218 the internal copper clusters. Further investigation revealed that the SOD-like  
219 performance of MOC-R was concentration-dependent, with increased activity  
220 observed as the concentration of MOC-R increased (Figure 2B). Additionally, EPR  
221 spectrometry confirmed the  $\cdot\text{O}_2^-$  scavenging capability of MOC-R nanozymes, as  
222 evidenced by a significant reduction in EPR signals upon the addition of MOC-R  
223 despite the signal overlap of TEMPO within MOC-R and  $\cdot\text{O}_2^-$  (Figure 2C). The SOD-  
224 like specific activity of MOC-R is calculated to be 3.16 U/mg (Figure S16) and  $\text{EC}_{50}$  is  
225 about 108  $\mu\text{g}/\text{mL}$ .

226 Following the disproportionation of  $\cdot\text{O}_2^-$ , hydrogen peroxide ( $\text{H}_2\text{O}_2$ ) was further  
227 catalyzed by catalase (CAT) into water and oxygen. We assessed  $\text{H}_2\text{O}_2$  consumption  
228 and oxygen generation using a dissolved oxygen detector to validate the CAT-  
229 mimicking activities of MOC-R nanozyme (Figure 2D) [47].  $\text{Cu}(\text{OAc})_2\cdot\text{H}_2\text{O}$ , MOC, and  
230 MOC-R all exhibited significant CAT-like activities, with MOC showing better activity  
231 and MOC-R demonstrating the highest. The superior CAT-like activity of the

232 assembled MOC compared to dissolved  $\text{Cu}(\text{OAc})_2 \cdot \text{H}_2\text{O}$  may also stem from  
 233 differences in active species. The MOC-R, integrating both active radicals and copper  
 234 clusters [48], enhanced CAT-like activity, primarily attributed to the active copper  
 235 clusters and assisted by the external TEMPO moieties. The elimination rates for MOC-R  
 236 R were concentration-dependent, with higher quantities of MOC-R accelerating  $\text{H}_2\text{O}_2$   
 237 catalysis (Figure 2E). Moreover, CAT-like kinetics, determined by oxygen generation,  
 238 confirmed that MOC-R nanozyme exhibited excellent CAT-like activity in converting  
 239  $\text{H}_2\text{O}_2$  into water and oxygen in a concentration-dependent manner (Figure S17). To  
 240 further determine the CAT-like activity of MOC-R, a kinetic analysis was carried out.  
 241 The Michaelis–Menten constant ( $K_m$ ) value of MOC-R with  $\text{O}_2$  as substrate was  
 242 calculated by the Michaelis–Menten equation to be 0.516 mM, and the maximum  
 243 velocity ( $V_m$ ) value was 7.743 mg/L/min (Figure 2F). Collectively, MOC-R  
 244 demonstrated excellent SOD- and CAT-like activities *in vitro* benefiting from the  
 245 synergism between external TEMPO moieties and internal copper clusters. Further,  
 246 we also estimated the radical scavenging ability of MOC-R (Figure S18-19). The  
 247 inhibition of hydroxyl radicals and ABTS radicals of MOC-R were larger than 80% at  
 248 concentrations of 0.40 and 0.66 mg/mL, respectively.



249

250 **Figure 2.** The antioxidant enzyme-like activities of MOC-R nanozyme. (A) The SOD-  
251 like activities of different groups. (B) Correlation between the amount of MOC-R and  
252 its SOD-like activity. (C) EPR detection of  $\cdot\text{O}_2^-$  signals under varying conditions. (D)  
253 Kinetics of  $\text{O}_2$  generation for CAT-like activity of MOC-R. (E) Impact of MOC-R amount  
254 on its CAT-like activity. (F) Kinetic analysis and Michaelis-Menten fitting of the CAT-  
255 like activity of MOC-R.


256

## 257 **The *in vitro* Cellular Protective and ROS-Scavenging Efficacy of MOC-R** 258 **Nanozyme**

259 To explore the antioxidant potential of MOC-R in biomedical applications, we focused  
260 on its biocompatibility firstly. Initial assessments included methyl thiazolyl tetrazolium  
261 (MTT) [49] assays and hemolysis tests at the cellular level. Human kidney-2 (HK-2)  
262 cells demonstrated a survival rate exceeding 90% across various MOC-R  
263 concentrations (0-160  $\mu\text{g}/\text{mL}$ ), indicating excellent biocompatibility (Figure 3A).  
264 Hemolysis rates remained exceptionally low, even at high MOC-R concentrations (160  
265  $\mu\text{g}/\text{mL}$ ), further confirming its minimal toxicity to erythrocytes (Figure 3B). Cellular  
266 uptake of MOC-R was assessed using inductively coupled plasma mass spectrometry  
267 (ICP-MS), revealing increased MOC-R content in HK-2 cells with prolonged incubation  
268 (Figure 3C). The ultrasmall size of MOC-R and its non-robust  $\text{Cu}_2(\text{COO}^-)_4$  cluster  
269 facilitated gradual release from the cells in either integrated or decomposed forms.

270 Subsequently, we evaluated the cellular protective capacity of MOC-R nanozyme  
271 against stressors induced by  $\text{H}_2\text{O}_2$  or hypoxia/reoxygenation (H/R) exposure (Figure  
272 3D-E). MTT assay results showed a significant reduction in HK-2 cell viability with  $\text{H}_2\text{O}_2$   
273 treatment or H/R exposure compared to controls. MOC-R treatment, however, notably  
274 mitigated these adverse effects and preserved cell viability, highlighting its potential as  
275 a protective agent against oxidative stress. To elucidate MOC-R's mechanism, we  
276 assessed its *in vitro* antioxidant efficacy using the DCFH-DA [50] probe through flow  
277 cytometry (Figure 3F). H/R treatment elevated ROS levels in HK-2 cells, with L-R, MOC,  
278 and MOC-R all demonstrating ROS scavenging abilities. MOC-R proved significantly

279 more effective than the other groups, underscoring its potent antioxidant performance.  
 280 We subsequently quantified the mRNA expression levels of inflammation-related  
 281 cytokines in HK-2 cells following H/R injury. Our results demonstrated that the mRNA  
 282 expression of pro-inflammatory cytokines (TNF- $\alpha$ , IL-2, and IL-6) significantly  
 283 increased after H/R injury, while the mRNA expression of the anti-inflammatory  
 284 cytokine IL-10 significantly decreased. As expected, treatment with the MOC-R  
 285 nanozyme markedly reversed these changes (Figure 3G). Moreover, Annexin V/PI  
 286 staining revealed that MOC-R significantly reduced H/R-induced apoptosis in HK-2  
 287 cells, indicating that MOC-R not only attenuates inflammation but also enhances cell  
 288 survival under conditions of oxidative stress (Figure 3H).



289  
 290 **Figure 3.** The *in vitro* cellular protective and ROS-scavenging efficacy of MOC-R  
 291 nanozyme. (A) The impact of MOC-R on HK-2 cell viability assessed using the MTT  
 292 assay. (B) Assessment of hemolytic activity of double-distilled water (DDW) or MOC-

293 R on HK-2 cells. (C) Cellular uptake of MOC-R in HK-2 cells. (D) MTT assay of MOC-  
294 R on H<sub>2</sub>O<sub>2</sub> treated HK-2 cells. (E) MTT assay of MOC-R on H/R assaulted HK-2 cells.  
295 (F) Flow cytometry and fluorescence intensity analysis to evaluate the influence of  
296 various treatments on HK-2 cells post H/R. (G) The mRNA levels of TNF- $\alpha$ , IL-2, IL-6,  
297 and IL-10 in HK-2 cells following H/R. (H) Flow cytometry analysis using Annexin V/PI  
298 staining to determine apoptosis of HK-2 cells after H/R. Data are presented as mean  
299  $\pm$  s.d. ns  $p > 0.05$ , \*  $p < 0.05$ , \*\*  $p < 0.01$ .

300

### 301 **MOC-R Nanozyme Protected Against Renal I/R Injury**


302 Firstly, the *in vivo* biocompatibility of MOC-R nanozyme was evaluated by intravenous  
303 injection of twice the usual dose. Two days later, the major organs were harvested and  
304 underwent histological analysis via H&E staining (Figure S20) [51]. The outcomes  
305 demonstrated that the histological injury of all groups of mice were difficult to detect,  
306 thereby indicating that MOC-R nanozyme did not inflict any conspicuous damage on  
307 the mice, ascertaining the favorable *in vivo* biocompatibility of MOC-R. Next, ICP-MS  
308 was employed to analyze the biodistribution at diverse time points subsequent to the  
309 injection of MOC-R solution, serving as an approach to explore the protective  
310 mechanism of MOC-R nanozyme in renal I/R injury (Figure 4A). Evidently, the  
311 concentration of MOC-R nanozyme in the bloodstream decreased over time, and the  
312 spleen and I/R kidney displayed the highest levels of MOC-R accumulation among the  
313 organs analyzed. The accumulation of MOC-R in the I/R-injured kidney can be  
314 attributed to the increased vascular permeability resulting from I/R injury, which  
315 disrupts endothelial cell junctions and triggers the release of pro-inflammatory  
316 mediators, thereby compromising the integrity of the vascular barrier. Moreover, owing  
317 to the ultrasmall particle size of MOC-R, a considerable portion had been metabolized  
318 within 24 h across all the examined tissues.

319 Oxidative stress arises from an imbalance between the production of ROS and the  
320 body's ability to detoxify these reactive intermediates or repair the resulting damage.  
321 This imbalance can lead to cellular dysfunction, tissue damage, and ultimately, organ

322 failure. We therefore evaluated the protective role of MOC-R nanozyme in renal I/R  
323 injury. All mice in the study were subjected to 30 min of ischemia. Renal tissues of  
324 mice in the I/R group all manifested substantial tubular necrosis and impairment after  
325 I/R injury. In contrast, mice treated with the L-R and MOC groups exhibited lessened  
326 tubular necrosis and damage after I/R injury; however, the effect was rather low. This  
327 was likely because molecular L-R was so prone to be cleared out and difficult to exert  
328 its effect. Nevertheless, mice treated with MOC-R exhibited significant alleviation of  
329 tubular and renal damage following I/R injury, as evidenced by minimal loss of brush  
330 border, limited intratubular debris, and reduced glomerular congestion. In contrast, the  
331 other groups displayed more pronounced tubular necrosis (Figure 4B-C). The renal  
332 protective effects of MOC-R were further examined by assessing creatinine and blood  
333 urea nitrogen (BUN) levels following I/R injury (Figure 4D). The outcomes indicated  
334 that both creatinine and BUN levels progressively increased and peaked at 24 h after  
335 I/R injury, then began to decline after 24 h. In contrast to the I/R group, L-R or MOC  
336 treatments slightly reduced the levels of creatinine and BUN, while the levels dropped  
337 significantly after MOC-R treatment. Given that MOC-R nanozyme exhibited its anti-  
338 oxidative capability *in vitro*, we next verified whether the amelioration of oxidative  
339 stress constitutes the underlying mechanism through which MOC-R nanozyme confers  
340 renal protection against I/R injury. By utilizing dihydroethidium (DHE), an intracellular  
341 superoxide indicator capable of being oxidized by superoxide to yield a red fluorescent  
342 product, we discovered that the fluorescence intensity of DHE-stained kidney tissue  
343 was augmented subsequent to I/R insult, indicating a high degree of ROS generation  
344 (Figure 4E-F). This increase was mitigated by L-R or MOC treatment, and was further  
345 diminished by MOC-R nanozyme treatment, demonstrating that MOC-R nanozyme  
346 inhibited I/R-induced oxidative stress in the kidneys [52,53].

347 Kidney injury molecule-1 (KIM-1), a biomarker of kidney injury, is expressed at an  
348 extremely low level in healthy kidneys and promptly upregulated following damaging  
349 events [54]. Neutrophil gelatinase-associated lipocalin (NGAL), a small protein  
350 belonging to the lipocalin family, is physiologically produced at a minimal level but rises

351 under harmful circumstances. We then tested KIM-1 and NGAL using  
 352 immunofluorescence to evaluate the biomarkers expression in injured kidneys.  
 353 Subsequently, we employed immunofluorescence to visualize KIM-1 and NGAL for  
 354 evaluating the molecular changes occurring in injured kidneys (Figure 4G-I). The  
 355 results revealed that the expression of NGAL and KIM-1 was significantly up-regulated  
 356 in I/R mice. However, no significant effect was observed after treatment with L-R and  
 357 MOC, and a marked decrease in the expression of NGAL and KIM-1 was detected  
 358 after treatment with MOC-R, indicating that MOC-R significantly changed the  
 359 expression patterns of I/R induced renal damage.  
 360



361  
 362 **Figure 4.** The protective effect of MOC-R nanozyme against I/R injury. (A) The  
 363 biodistribution of MOC-R in diverse tissues as indicated by the copper concentration.  
 364 (B) Representative Hematoxylin and eosin staining of the kidney at 24 h post  
 365 reperfusion (10x and 20x). Vascular congestions are indicated by arrows. Scale bars

366 represent 100  $\mu$ m. (C) Assessment of kidney injury based on tubular injury scores. (D)  
367 Serum creatinine and BUN levels in renal I/R injury. (E) Representative  
368 immunofluorescence images of DHE expression at 24 h post reperfusion. Scale bars  
369 represent 100  $\mu$ m. (F) The count of the DHE positive cells. (G) Representative  
370 immunofluorescence images showing KIM-1 expression at 24 h post reperfusion. (H)  
371 Representative immunofluorescence images showing NGAL expression at 24 h post  
372 reperfusion. Scale bars represent 100  $\mu$ m. (I) The count of the KIM-1 and NGAL  
373 positive cells. Data are presented as mean  $\pm$  s.d. \*  $p < 0.05$ , \*\*  $p < 0.01$ .

374

### 375 **MOC-R Nanozyme Restricted I/R Induced Inflammatory Milieu and Programmed** 376 **Cell Death**


377 ROS are essential for the induction and maintenance of M1 macrophage polarization.  
378 Numerous studies have highlighted the role of ROS in activating both the NF- $\kappa$ B and  
379 p38/MAPK signaling pathways, which in turn promote pro-inflammatory gene  
380 expression in macrophages [55,56]. Immunofluorescence assays demonstrated that  
381 I/R insult augmented the expression of the M1 macrophage phenotype (CD86), yet L-  
382 R or MOC treatment marginally reversed the M1 phenotype to the M2 macrophage  
383 marker (CD206) [57]. Intriguingly, the expression of CD86 substantially declined  
384 concomitant with a notable increase in the expression of CD206 following MOC-R  
385 nanozyme treatment, which was precisely the converse of that in I/R kidneys (Figure  
386 5A-B). Given the significant role of M2 macrophages in kidney fibrosis, we utilized  
387 Masson's trichrome staining to assess collagen deposition in renal tissues and  
388 evaluate the long-term effects of MOC-R on renal fibrosis (Figure S21). Our results  
389 indicated that MOC-R did not increase collagen deposition, suggesting it does not  
390 promote fibrotic changes. Additionally, neutrophil infiltration after reperfusion was  
391 quantified by Immunofluorescence assays (with positive cells indicated by red  
392 fluorescence normalized to DAPI-stained nuclei). A considerable increase in  
393 neutrophils was noted in I/R-injured kidney compared to the sham group. While neither  
394 L-R nor MOC treatment proved effective in lowering neutrophil levels, a propensity that



395 was effectively alleviated by treatment with MOC-R nanozyme, which significantly  
396 decreased neutrophil levels (Figure 5C-D). We then measured the mRNA expression  
397 of inflammatory-related cytokines in kidney tissues following I/R injury (Figure 5E), and  
398 discovered that the mRNA expression of proinflammatory cytokines (TNF- $\alpha$ , IL-2, and  
399 IL-6) significantly increased after I/R injury, while the MOC-R nanozyme markedly  
400 decreased them. In contrast, upon I/R injury, the mRNA expression of the anti-  
401 inflammatory cytokine (IL-10) declined, whereas the MOC-R nanozyme elevated it to  
402 a considerable extent, albeit missing the significance. These findings demonstrated  
403 that the MOC-R nanozyme can not only inhibit the polarization of macrophages to the  
404 M1 phenotype and facilitate its polarization to the M2 phenotype but also enhance the  
405 suppression of the I/R-induced inflammatory response.

406 Autophagy is a regulated cellular process of self-degradation and is typically regarded  
407 as an inducible adaptive response to cellular stress. However, dysregulation or  
408 excessive activation of autophagy, such as that occurring during I/R injury, triggers  
409 autophagic cell death without caspase involvement. Herein, western blotting was  
410 performed to detect the expression levels of autophagy-related proteins (Beclin-1 and  
411 P62) in order to evaluate autophagic flux in kidneys following I/R injury (Figure 5F). As  
412 expected, MOC-R treatment significantly reduced the expression levels of Beclin-1 and  
413 P62 (Figure 5G). In line with the western blotting data, immunostaining targeting LC3  
414 manifested a pronounced increase in the number of autophagosomes within the kidney  
415 tissue after I/R and a decrease subsequent to MOC-R nanozyme treatment. However,  
416 L-R or MOC treatment had no effect on the autophagy level in I/R kidneys (Figure 5H-  
417 I). Apoptosis is a tightly-regulated ATP-dependent process of programmed cell death  
418 that is activated by hypoxia due to ischemia and during ROS generation in reperfusion.  
419 The level of cellular apoptosis in I/R kidney was assessed using the TUNEL assay in  
420 this study (Figure 5J-K). Our findings indicated that the proportions of TUNEL-positive  
421 cells were significantly lower in mice treated with MOC-R than in the control group.  
422 These results indicated that the MOC-R nanozyme modulated the anti-inflammatory

423 response by alleviating oxidative stress, thereby reducing programmed cell death in  
 424 kidneys subjected to I/R injury.



425  
 426 **Figure 5.** MOC-R nanozyme restricted I/R induced inflammatory milieu and  
 427 programmed cell death. (A) Representative immunofluorescence images showing  
 428 CD86 and CD206 expression at 24 h post reperfusion. Scale bars represent 100  $\mu$ m.  
 429 (B) The count of the CD86 and CD206 positive cells. (C) Representative  
 430 immunofluorescence images showing MPO expression at 24 h post reperfusion. Scale  
 431 bars represent 100  $\mu$ m. (D) The count of the MPO positive cells. (E) The mRNA levels  
 432 of TNF- $\alpha$ , IL-2, IL-6, and IL-10 in renal tissue. (F) Expression of Beclin-1 and P62  
 433 detected by western blotting assay. (G) The relative densities of the bands in each lane  
 434 were analyzed and normalized to  $\beta$ -actin. (H) Representative immunofluorescence

435 images showing LC3 expression at 24 h post reperfusion. (I) The count of the cells  
436 with LC3 positive autophagosomes. (J) Representative immunofluorescence images  
437 showing TUNEL expression at 24 h post reperfusion. Scale bars represent 100  $\mu\text{m}$ . (K)  
438 The count of the TUNEL positive cells. Data are presented as mean  $\pm$  s.d. \*  $p < 0.05$ .

439

## 440 **Conclusion**

441 In this study, an atomically precise, ultrasmall, and water-soluble cascade antioxidant  
442 nanozyme was constructed based on a metal organic cage integrating active organic  
443 radicals and metal clusters. Through the assembly of ligands containing radicals and  
444 copper ions, the water-soluble MOC-R could be obtained in a high yield. The particle  
445 size of MOC-R is approximately 7.0 nm, and it is negatively charged; these properties  
446 of MOC-R are beneficial for the clinical application of antioxidants *in vivo*. The MOC-R  
447 compound not only demonstrates SOD-like activity and CAT-like activity, but also  
448 showcases remarkable potential in the field of antioxidant therapy. Its SOD-like activity  
449 is primarily attributed to the presence of TEMPO, a key component that contributes to  
450 its free radical scavenging abilities. Meanwhile, the CAT-like activity of MOC-R arises  
451 from the unique properties of its copper clusters, which enable it to efficiently neutralize  
452 ROS. As a result, this cascading nanozyme is capable of efficiently scavenging harmful  
453 ROS, particularly  $\bullet\text{O}_2^-$  and  $\text{H}_2\text{O}_2$ , under stressful conditions. MOC-R also displays  
454 excellent biocompatibility and significant ROS-scavenging ability at both *in vitro* and *in*  
455 *vivo* levels, exerting exceptional renoprotective potency by influencing the anti-  
456 inflammatory status of the immune response and regulating programmed cell death. In  
457 conclusion, the multifaceted capabilities of MOC-R make it a compelling candidate for  
458 further exploration in biomedical research aimed at combating oxidative stress-related  
459 disorders.

460

## 461 **Materials and Methods**

### 462 **SOD-like activity**

463 SOD-like activity was determined using the nitrogen blue tetrazolium (NBT) method.  
464 Under UV irradiation, riboflavin and methionine can react to produce  $\cdot\text{O}_2^-$ , which  
465 reduces NBT to generate blue methylhydrazone with a maximum absorption  
466 wavelength of 560 nm. However, SOD can scavenge  $\cdot\text{O}_2^-$  and inhibit the generation of  
467 methylhydrazone. Therefore, the higher the SOD-like activity, the lower the amount of  
468 the reduction product (methylhydrazone), and the lower the absorbance at 560 nm.  
469 Thus, the decrease in absorbance at 560 nm confirms the role of SOD-like activity.  
470 The PBS solution of samples (2 mg/mL, 90  $\mu\text{L}$ ) were added to the mixture of NBT (1  
471 mg/mL, 0.5 mL), Met (30 mg/mL, 0.5 mL), EDTA- $\text{Na}_2$  (0.4 mg/mL, 0.3 mL), riboflavin  
472 (1 mg/mL, 0.5 mL) and PBS solution (pH = 7.4, 2 mL) and incubated together under  
473 constant UV irradiation for 60 s to test the SOD-like activity. The experiments were  
474 divided into five groups due to the different samples: (1) PBS; (2)  $\text{Cu}(\text{OAc})_2\cdot\text{H}_2\text{O}$ ; (3)  
475 L-R; (4) MOC; (5) MOC-R. The concentration-dependent SOD-like activities were also  
476 determined by varying the concentrations of MOC-R under the same conditions and  
477 incubated under UV irradiation for 60 s.  
478 To further investigate the SOD-like activity of MOC-R, we employed EPR spectroscopy  
479 for a more intuitive assessment. 5,5-Dimethyl-1-pyrroline N-oxide (DMPO) was used  
480 as a potent free radical trapping agent, capable of forming spin adducts upon  
481 interaction with the  $\cdot\text{O}_2^-$  radical. The spin adducts, which can be detected by EPR,  
482 provide a direct measurement of the  $\cdot\text{O}_2^-$  radical concentration in the reaction system.  
483 The reaction mixture consisted of the following components: Met (130 mM, 0.25 mL),  
484 EDTA- $\text{Na}_2$  (0.1 mM, 0.25 mL),  $\text{H}_2\text{O}$  (0.20 mL), MOC-R (2 mg/mL, 0.05 mL), riboflavin  
485 (0.02 mM, 0.25 mL), DMPO (100 mM, 70  $\mu\text{L}$ ), and phosphate buffer (pH 7.4, 50 mM,  
486 1.68 mL). The mixture was thoroughly mixed and then placed into a nuclear magnetic  
487 resonance tube for subsequent UV irradiation at two time points: 0 s and 20 s, followed  
488 by EPR spectrum analysis.

489

490  **$\cdot\text{O}_2^-$  Inhibition Rate**

491 Mixture of NBT (1 mg/mL, 0.4 mL), Met (30 mg/mL, 0.4 mL), EDTA-Na<sub>2</sub> (0.4 mg/mL,  
492 0.25 mL), riboflavin (1 mg/mL, 0.4 mL) and PBS solution (pH = 7.4, 1.85 mL) to obtain  
493 the detection working solution. Subsequently, MOC-R solutions (0.35-2.45 mg/mL, 200  
494 μL) or PBS (200 μL) was added to above detection working solution and immediately  
495 irradiated it with ultraviolet light. Record the changes in absorbance between the  
496 sample and blank, calculate the inhibition rate, and obtain the enzyme activity unit.

$$497 \text{ Inhibition rate (\%)} = (A_b - A_s)/A_b \times 100$$

498 where  $A_b$  is the absorbance of the blank and  $A_s$  is the absorbance of the sample.

499

### 500 **CAT-like activity**

501 CAT-like activity was determined using a dissolved oxygen meter. Oxygen produced  
502 was measured at room temperature by using a specific oxygen electrode on a split  
503 dissolved oxygen meter (SW9403). Sample (2 mg/mL, 100 μL) and H<sub>2</sub>O<sub>2</sub> solution (30%,  
504 200 μL) was added to water (14.94 mL), and the concentration (in mg/L) of produced  
505 oxygen was recorded from 0 to 5 min. To assess the CAT-like activity, five samples  
506 were set up: (1) PBS; (2) Cu(OAc)<sub>2</sub>·H<sub>2</sub>O; (3) L-R; (4) MOC; and (5) MOC-R. In addition,  
507 different amounts (50, 100, 150, and 200 μL) of MOC-R solution (2 mg/mL) were added  
508 to the final volume of the buffer solution (15 mL), and their corresponding CAT-like  
509 activity was determined.

510

### 511 **CAT-like Kinetics**

512 A series of solutions of hydrogen peroxide (0.10-12.68 mM in PBS, 25 mL) was  
513 prepared, then MCO-R solution (1 mg/mL in PBS, 0.10 mL) was added. The dissolved  
514 oxygen in the above mixture was immediately monitored for 5 min using a dissolved  
515 oxygen analyzer. The corresponding reaction rate and hydrogen peroxide  
516 concentration were then fitted to the Michaelis-Menten equation to obtain the relevant  
517 reaction kinetics parameters.

518

### 519 **Hydroxyl radical scavenging**

520 The reaction mixture contains FeSO<sub>4</sub> (6 mM, 0.1 mL), hydrogen peroxide (6 mM, 0.1  
521 mL), and sample (0.15-2.4 mg/mL in PBS, 0.1 mL). The mixture was incubated at 37  
522 °C for 10 min, covered with Salicylic acid ethanol solution (6 mM, 0.1 mL), and then  
523 further incubated at 37 °C for 30 min. Measure the mixture at 510 nm using an enzyme-  
524 linked immunosorbent assay reader. Ultrapure water was used as a blank instead of  
525 the sample.

526 Hydroxyl radical scavenging activity (%) =  $(A_b - A_s)/A_b \times 100$

527 where  $A_b$  is the absorbance of the blank and  $A_s$  is the absorbance of the sample.

528

### 529 **ABTS radical scavenging activity**

530 The solutions of ABTS (7.0 mM in DDW), potassium persulfate (9.4 mM in DDW), and  
531 MOC-R (0.25-2.0 mg/mL in PBS) were prepared firstly. Mixing the solutions of ABTS  
532 and potassium persulfate in equal volume at room temperature in the dark for 12 h and  
533 then diluted for 20 times with PBS to obtain the ABTS working solution. Add ABTS  
534 working solution (0.2 mL) and samples (0.15-2.4 mg/mL in PBS, 0.1 mL) to each well  
535 on a 96 well plate, incubate for 30 min, and measure the absorbance at 734 nm using  
536 an enzyme-linked immunosorbent assay reader.

537 ABTS radical scavenging activity(%) =  $(A_b - A_s)/A_b \times 100$

538 where  $A_b$  is the absorbance of the blank and  $A_s$  is the absorbance of the sample.

539

### 540 **Cytotoxicity assay**

541 To assess the cytotoxic effect of MOC-R, HK-2 (7000 cells/well) cells were added into  
542 a 96 well plate, and cultured at 37 °C for 12 h. Different concentrations (0, 5, 10, 20,  
543 40, 80, 160 µg/mL, 10 µL) of MOC-R solution in PBS were added in cells and cultured  
544 for another 24 h. Afterwards, the cells were gently washed by PBS (pH 7.4) for three  
545 times. The Thiazolyl Blue Tetrazolium Bromide (MTT) solution (Beyotime, Shanghai)  
546 was added to each well individually and incubated for 4 h in the dark. Subsequently,  
547 the cell supernatant was collected using a micropipettor, followed by addition of 150  
548 µL of DMSO. After thorough agitation for 10 min to completely dissolve MTT crystals,

549 cell viability was assessed using a microplate reader at absorbance wavelengths of  
550 570 nm.

551

### 552 **Hemolysis assay**

553 The whole blood of healthy mice was collected in a 2 mL EP tube, and the blood was  
554 centrifuged at 2000 rpm for 5 min to remove the upper serum and obtain erythrocytes.

555 Then erythrocytes were washed three times with PBS, and 0.5 mL erythrocytes were  
556 diluted with 10 mL PBS. Then 0.5 mL of MOCs solution (5, 10, 20, 40, 80, 160 µg/mL),  
557 or DDW were added to 0.5 mL erythrocytes suspension, respectively. All sample tubes  
558 were kept at room temperature for 2 h and then centrifuged at 2000 rpm for 5 min.  
559 Finally, the experimental result was recorded by a camera.

560

### 561 **Cellular uptake**

562 ICP-MS was used to accurately measure the uptake of MOC-R by HK-2 cells. In the *in*  
563 *vitro* cell uptake assay, HK-2 cells were inoculated into 10 mm tissue plates at a density  
564 of 10,000 cells/mL and cultured for 24 h. After 24 h, MOC-R (10 µg/mL, final  
565 concentration) was added to each tissue plate and cultured for 2, 4, 8, or 12 h.

566 In the *in vitro* cell retention assay, HK-2 cells were inoculated onto 10-mm tissue plates  
567 at a density of 10,000 cells/mL, and after 24 h of incubation, MOC-R (10 µg/mL, final  
568 concentration) was added to each tissue plate and incubated for another 12 h. After  
569 that, the medium was extracted and replaced with fresh medium (without MOC-R).  
570 Cells were subsequently collected at the “12 + 4” h and “12 + 8” h time points. After  
571 trypsinization and centrifugation steps, the cell pellet was washed three times with  
572 phosphate buffer solution. The samples were digested using a solution containing  
573 HNO<sub>3</sub> (68%, 0.25 mL) and HCl (38%, 0.75 mL), and the digestion process lasted for 4  
574 h at a temperature of 110 °C. After cooling, the sample was diluted with HCl (2%) to a  
575 volume of 10 mL. The copper concentration was then determined by ICP-MS.

576

### 577 **Intracellular ROS scavenging ability**

578 Intracellular ROS levels were assessed using the fluorescent probe DCFH-DA. HK-2  
579 cells (7000 cells per well) were cultured in 6-well microtiter plates at 37 °C for 12 h. To  
580 induce hypoxia, Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub> solution (2 mM) was added to the culture medium and the  
581 cells were placed in a CO<sub>2</sub> incubator. The five experimental groups were designed as  
582 follows: (1) Control; (2) H/R; (3) H/R + L-R; (4) H/R + MOC; (5) H/R + MOC-R. The  
583 experimental groups (3-5) were added with samples (10 µg/mL, final concentration)  
584 and cultured at 37 °C for another 6 h. The results were analyzed using flow cytometry  
585 (FACSymphony, BD Biosciences, NJ).

586

### 587 **Real-time PCR analysis**

588 The total cellular or renal RNA was extracted using TRIzol reagent (Invitrogen,  
589 Shanghai) according to the manufacturer's instructions. cDNA was transcribed using  
590 a Superscript III Reverse Transcriptase Kit (Invitrogen) and oligo d(T) (Applied  
591 Biosystems, Waltham, MA, USA). Quantitative RT-PCR analysis was performed with  
592 a SYBR RT-PCR kit (Takara, Tokyo) and the StepOne Real-Time PCR System  
593 (Applied Biosystems). All reactions were conducted in a 20 µL reaction volume in  
594 triplicate. The relative expression levels for a target gene were normalized against  
595 GAPDH. Primers used for RT-PCR analysis are as follows: TNF-α (5'-AAG CCT GTA  
596 GCC CAC GTC GTA-3', 5'-GGC ACC ACT AGT TGG TTG TCT TTG-3'), IL-2 (5'-CCA  
597 TGA TGC TCA CGT TTA AAT TTT-3', 5'-CAT TTT CCA GGC ACT GGA GAT G-3'),  
598 IL-6 (5'-ACA ACC ACG GCCTTC CCT ACT T-3', 5'-CAC GAT TTC CCA GAG AAC  
599 ATG TG-3'), IL-10 (5'-GCT TTA CTG ACT GGC ATG AG-3', 5'-CGC AGC TCT AGG  
600 AGC ATG TG-3'), and GAPDH (5'-TGA CCA CAG TCC ATG CCA TC-3', 5'-GAC GGA  
601 CAC ATT GGG GGT AG-3').

602

### 603 **Cellular apoptosis assay**

604 An Annexin V-FITC/PI Apoptosis Detection Kit (Beyotime) was utilized to evaluate cell  
605 apoptosis. Cells were washed twice with cold PBS and subsequently harvested using  
606 trypsin without EDTA. The cells were resuspended in 195 µL of binding buffer. Next, 5



607  $\mu\text{L}$  of Annexin V-FITC and 10  $\mu\text{L}$  of propidium iodide staining solution were added,  
608 followed by incubation in an ice bath protected from light for 15 min. The percentage  
609 of apoptotic cells was quantified by flow cytometry (FACSymphony, BD Biosciences,  
610 NJ).

611

### 612 **Animal experimentation**

613 Animal and Ethics Statement: C57BL/6 mice (female, 7-8 weeks old) were obtained  
614 from Shanghai Laboratory Animal Center, China. All animal experiments were  
615 performed in accordance with the guidelines of the National Institute of Health for the  
616 Care and Use of Laboratory Animals and approved by the Scientific Investigation  
617 Committee of Shanghai Changzheng Hospital (No. 202403013A).

618

### 619 **Pharmacokinetics analysis**

620 The mice were sacrificed at the designated time points. Blood and all organs were  
621 collected, weighted and digested in a solution containing 0.25 mL  $\text{HNO}_3$  (68%) and  
622 0.75 mL HCl (38%) for 12 h at 110 °C. After cooling, the samples were diluted with HCl  
623 (2%) to 10 mL. Cu contents were then detected by ICP-MS.

624

### 625 **Induced renal ischemia/reperfusion model**

626 Mice were anesthetized with sodium pentobarbital (50 mg/kg, intraperitoneal injection),  
627 and after a right flank incision, the right renal hilum was clamped with a noninvasive  
628 microaneurysm clamp (Shanghai Medical Devices Co., Ltd., Shanghai, China) for 30  
629 min. The left contralateral kidney was considered as a sham operation. The incision  
630 was temporarily closed during ischemia. After removal of the microaneurysm clip, the  
631 lateral abdominal incision was closed after visual confirmation of reperfusion. Body  
632 temperature was maintained using an adjustable heating pad. All mice were  
633 intraperitoneally injected with 0.5 mL of isotonic saline after surgery, and L-R, MOC, or  
634 MOC-R (250  $\mu\text{g}/\text{mL}$ , 400  $\mu\text{L}$ ) were injected into different mice through the tail vein and  
635 were executed at the indicated reperfusion time points.

636

### 637 **Histopathological assessment**

638 Mice were executed at the indicated time points, and mouse kidneys were coronal  
639 sectioned, fixed in 10% buffered formalin, paraffin-embedded, and sectioned at a  
640 thickness of 3  $\mu$ m sections were stained with hematoxylin and eosin to assess tissue  
641 damage. Kidney sections were blindly labeled and randomized for observation by two  
642 researchers. The extent of renal tubular injury was assessed semiquantitatively and  
643 pathologically on a scale of 0 to 4: 0 = no recognizable injury; 1 = single cell necrosis;  
644 2 = necrosis of all cells in the adjacent convoluted tubule, with surrounding tubules  
645 surviving; 3 = necrosis confined to the distal one-third of the proximal convoluted tubule,  
646 with a band of necrosis spanning the endothelial layer; 4 = necrosis affecting all three  
647 segments of the proximal convoluted tubule.

648

### 649 **Immunofluorescence assay**

650 Kidney frozen sections were processed according to standard protocols. Subsequently,  
651 the sections were incubated overnight with anti-DHE, KIM-1, NGAL, CD86/CD206,  
652 MPO, LC3 or TUNEL primary antibody provided by Beyotime Biotech. After that, the  
653 sections were rinsed three times with PBS and then incubated with secondary antibody  
654 for 1 h at room temperature. Cell nuclei were stained using DAPI. Finally, the slides  
655 were examined and imaged under a fluorescence microscope (Nikon80i, Tochigi,  
656 Japan).

657

### 658 **Western blotting**

659 Tissues were rinsed with PBS twice and lysed in ice-cold RIPA buffer (Roche, Basel,  
660 Switzerland) containing phosphatase and protease inhibitors. Sample proteins were  
661 then subjected to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and  
662 transferred to nitrocellulose membranes. Membranes were probed with Beclin-1 and  
663 P62 antibodies from Beyotime Biotech. The relative quantity of proteins was  
664 determined by a densitometer software (ImageJ, NY).

665

## 666 **Masson staining**

667 The kidney tissue was fixed in 4% paraformaldehyde. Slices of the paraffin-coated  
668 kidney samples were taken. Masson's Trichrome Stain Kit (Beyotime) was used on  
669 kidney tissues. Kidney sections were blindly labeled and randomized for observation  
670 by two researchers. The Masson staining was utilized to semi-quantitatively analyze  
671 the collagen volume fraction, which is defined as the proportion of collagen-positive  
672 blue area to the total tissue area. The Image J software was employed for this purpose.

673

## 674 **Statistical analysis**

675 Statistical significance was determined utilizing an ANOVA followed by Bonferroni's  
676 test correction using GraphPad Prism 10 (La Jolla, USA). The results are expressed  
677 as the mean  $\pm$  standard deviation (SD). In every case,  $p < 0.05$  was considered  
678 statistically significant.

679

## 680 **Abbreviations**

681 AFM: atomic force microscopy; BUN: blood urea nitrogen; CAT: catalase; DAPI: 4',6-  
682 diamidino-2-phenylindole; DCFH-DA: 2',7'-dichlorodihydrofluorescein diacetate; DLS:  
683 dynamic light scattering; DHE: dihydroethidium; DMPO: 5,5-dimethyl-1-pyrroline N-  
684 oxide; EPR: electron paramagnetic resonance; FBS: fetal bovine serum; FT-IR: fourier  
685 transform infrared spectroscopy; H/R: hypoxia/reoxygenation; H&E: hematoxylin and  
686 eosin; HK-2: Human kidney-2; I/R: ischemia-reperfusion; ICP-MS: inductively coupled  
687 plasma mass spectrometry; KIM-1: kidney injury molecule-1; MALDI-TOF: matrix  
688 assisted laser desorption/ionization time of flight; MOC: metal-organic cage; MOC-R:  
689 radical-functionalized metal-organic cage; MTT: methyl thiazolyl tetrazolium; NBT:  
690 nitrotetrazolium blue chloride; NGAL: neutrophil gelatinase-associated lipocalin; ROS:  
691 reactive oxygen species; SEC: size exclusion chromatography; SOD: superoxide  
692 dismutase; TEMPO: 2,2,6,6-tetramethylpiperidin-1-oxyl; WB: western blot.

693

694 **Acknowledgements**

695 This work was supported by the Fundamental Research Funds for the Central  
696 Universities (YG2023QNA04, YG2022QN027), and Shanghai Municipal Health  
697 Commission Clinical Research Project (20214Y0521).

698

699 **Competing Interests**

700 The authors have declared that no competing interest exists.

701

702 **References**

- 703 1. Wang F-L, Wang W-Z, Zhang F-F, Peng S-Y, Wang H-Y, Chen R, et al. Heat  
704 exposure and hospitalizations for chronic kidney disease in China: a nationwide time  
705 series study in 261 major Chinese cities. *Mil Med Res.* 2023; 10: 41.
- 706 2. Tyuryaeva I, Lyublinskaya O. Expected and unexpected effects of pharmacological  
707 antioxidants. *Int J Mol Sci.* 2023; 24: 9303.
- 708 3. Geo HN, Murugan DD, Chik Z, Norazit A, Foo YY, Leo BF, et al. Renal nano-drug  
709 delivery for acute kidney injury: Current status and future perspectives. *J Control*  
710 *Release.* 2022; 343: 237–54.
- 711 4. Qiu Y, Tan G, Fang Y, Liu S, Zhou Y, Kumar A, et al. Biomedical applications of  
712 metal–organic framework (MOF)-based nano-enzymes. *New J Chem.* 2021; 45:  
713 20987–1000.
- 714 5. Mishra P, Lee J, Kumar D, Louro RO, Costa N, Pathania D, et al. Engineered  
715 nanoenzymes with multifunctional properties for next-generation biological and  
716 environmental applications. *Adv Funct Mater.* 2022; 32: 2108650.
- 717 6. Yu Z, Lou R, Pan W, Li N, Tang B. Nanoenzymes in disease diagnosis and  
718 therapy. *Chem Commun.* 2020; 56: 15513–24.
- 719 7. Wu J, Wang X, Wang Q, Lou Z, Li S, Zhu Y, et al. Nanomaterials with enzyme-like  
720 characteristics (nanozymes): next-generation artificial enzymes (II). *Chem Soc Rev.*  
721 2019; 48: 1004–76.
- 722 8. Shi J, Shu R, Shi X, Li Y, Li J, Deng Y, et al. Multi-activity cobalt ferrite/MXene  
723 nanoenzymes for drug-free phototherapy in bacterial infection treatment. *RSC Adv.*  
724 2022; 12: 11090–9.
- 725 9. Li W-L, Head-Gordon T. Catalytic principles from natural enzymes and  
726 translational design strategies for synthetic catalysts. *ACS Cent Sci.* 2021; 7: 72–80.
- 727 10. Zhang F, Zeng T, Wu R. QM/MM modeling aided enzyme engineering in natural  
728 products biosynthesis. *J Chem Inf Model.* 2023; 63: 5018–34.
- 729 11. Yan H, Shao D, Lao Y, Li M, Hu H, Leong KW. Engineering cell membrane-  
730 based nanotherapeutics to target inflammation. *Adv Sci.* 2019; 6: 1900605.

- 731 12. Liu T, Xiao B, Xiang F, Tan J, Chen Z, Zhang X, et al. Ultrasmall copper-based  
732 nanoparticles for reactive oxygen species scavenging and alleviation of inflammation  
733 related diseases. *Nat Commun.* 2020; 11: 2788.
- 734 13. Razzaghi M, Homaei A, Vianello F, Azad T, Sharma T, Nadda AK, et al. Industrial  
735 applications of immobilized nano-biocatalysts. *Bioprocess Biosyst Eng.* 2022; 45:  
736 237–56.
- 737 14. Li C, Hang T, Jin Y. Atomically Fe-anchored MOF-on-MOF nanozyme with  
738 differential signal amplification for ultrasensitive cathodic electrochemiluminescence  
739 immunoassay. *Exploration.* 2023; 3: 20220151.
- 740 15. Li Q, Wu T, Akakuru OU, Song N, Liu W, Jiang W, et al. A dual synergetic  
741 nanoreactor for managing Parkinson's disease by regulating inflammation and  
742 mitigating oxidative damage. *Adv Funct Mater.* 2023; 33: 2214826.
- 743 16. Huang Y, Liu C, Pu F, Liu Z, Ren J, Qu X. A GO–Se nanocomposite as an  
744 antioxidant nanozyme for cytoprotection. *Chem Commun.* 2017; 53: 3082–5.
- 745 17. Ahmedova A, Momekova D, Yamashina M, Shestakova P, Momekov G, Akita M,  
746 et al. Anticancer potencies of Pt<sup>II</sup>- and Pd<sup>II</sup>-linked M<sub>2</sub>L<sub>4</sub> coordination capsules with  
747 improved selectivity. *Chem Asian J.* 2016; 11: 474–7.
- 748 18. Kang Y, Li C, Shi H, Zhang A, Huang C, Zhou C, et al. Photothermally enhanced  
749 dual enzyme-mimic activity of gold-palladium hybrid nanozyme for cancer therapy.  
750 *Chin J Chem.* 2023; 41: 3189–96.
- 751 19. Villalba-Rodríguez AM, Martínez-Zamudio LY, Martínez SAH, Rodríguez-  
752 Hernández JA, Melchor-Martínez EM, Flores-Contreras EA, et al. Nanomaterial  
753 constructs for catalytic applications in biomedicine: nanobiocatalysts and nanozymes.  
754 *Top Catal.* 2023; 66: 707–22.
- 755 20. Huang Y, Ren J, Qu X. Nanozymes: classification, catalytic mechanisms, activity  
756 regulation, and applications. *Chem Rev.* 2019; 119: 4357–412.
- 757 21. Ferreira CA, Ni D, Rosenkrans ZT, Cai W. Scavenging of reactive oxygen and  
758 nitrogen species with nanomaterials. *Nano Res.* 2018; 11: 4955–84.
- 759 22. Huang C, Deng Y, Ma R, Ge H, Gong F, Yang J, et al. A metal–organic cage-  
760 derived cascade antioxidant nanozyme to mitigate renal ischemia-reperfusion injury.  
761 *Nanoscale.* 2024; 16: 9406–11.
- 762 23. Huang C, Li J, Zhu X, Wang Y. Chiral metal–organic cages decorated with  
763 binaphthalene moieties. *Nanoscale.* 2023; 15: 19475–9.
- 764 24. Yu C, Yang P, Zhu X, Wang Y. Planet-satellite cage hybrids: covalent organic  
765 cages encircling metal organic cage. *Sci China Chem.* 2022; 65: 858–62.
- 766 25. Wang Y-P, Zhang Y, Duan X-H, Mao J-J, Pan M, Shen J, et al. Recent progress  
767 in metal-organic cages for biomedical application: Highlighted research during 2018–  
768 2023. *Coord Chem Rev.* 2024; 501: 215570.
- 769 26. Zhu C, Pan M, Su C. Metal-organic cages for biomedical applications. *Isr J*  
770 *Chem.* 2019; 59: 209–19.
- 771 27. Wang J-S, Wu K, Yin C, Li K, Huang Y, Ruan J, et al. Cage-confined  
772 photocatalysis for wide-scope unusually selective [2 + 2] cycloaddition through  
773 visible-light triplet sensitization. *Nat Commun.* 2020; 11: 4675.

- 774 28. Guo J, Fan Y, Lu Y, Zheng S, Su C. Visible-light photocatalysis of asymmetric  
775 [2+2] cycloaddition in cage-confined nanospace merging chirality with triplet-state  
776 photosensitization. *Angew Chem Int Ed*. 2020; 59: 8661–9.
- 777 29. El-Sayed E-SM, Yuan YD, Zhao D, Yuan D. Zirconium metal–organic cages:  
778 synthesis and applications. *Acc Chem Res*. 2022; 55: 1546–60.
- 779 30. Samanta SK, Isaacs L. Biomedical applications of metal organic polygons and  
780 polyhedra (MOPs). *Coord Chem Rev*. 2020; 410: 213181.
- 781 31. Wang Z, He L, Liu B, Zhou L-P, Cai L-X, Hu S-J, et al. Coordination-assembled  
782 water-soluble anionic lanthanide organic polyhedra for luminescent labeling and  
783 magnetic resonance imaging. *J Am Chem Soc*. 2020; 142: 16409–19.
- 784 32. Sun D, Feng X, Zhu X, Wang Y, Yang J. Anticancer agents based on metal  
785 organic cages. *Coord Chem Rev*. 2024; 500: 215546.
- 786 33. Sun D, Deng Y, Dong J, Zhu X, Yang J, Wang Y. Heterometallic organic cages  
787 as cascade antioxidant nanozymes to alleviate renal ischemia-reperfusion injury.  
788 *Chem Eng J*. 2024; 497: 154648.
- 789 34. Yin P, Sun D, Deng Y, Zhu X, Wang Y, Yang J. Metal-organic cage as a  
790 theranostic nanoplatform for magnetic resonance imaging guided chemodynamic  
791 therapy. *Theranostics*. 2024; 14: 4861–73.
- 792 35. Wang K, Zhang Y, Mao W, Feng W, Lu S, Wan J, et al. Engineering ultrasmall  
793 ferroptosis-targeting and reactive oxygen/nitrogen-species-scavenging nanozyme for  
794 alleviating acute kidney injury. *Adv Funct Mater*. 2022; 32: 2109221.
- 795 36. Zhang D-Y, Younis MR, Liu H, Lei S, Wan Y, Qu J, et al. Multi-enzyme mimetic  
796 ultrasmall iridium nanozymes as reactive oxygen/nitrogen species scavengers for  
797 acute kidney injury management. *Biomaterials*. 2021; 271: 120706.
- 798 37. Zhang S, Zhang X-D. Recent advances in the bioactive structure and application  
799 of single-atom nanozymes. *Nano Biomed Eng*. 2024; 16: 1–27.
- 800 38. Pattison DI, Lam M, Shinde SS, Anderson RF, Davies MJ. The nitroxide TEMPO  
801 is an efficient scavenger of protein radicals: Cellular and kinetic studies. *Free Radic*  
802 *Biol Med*. 2012; 53: 1664–74.
- 803 39. Yu H, Cao L, Li F, Wu Q, Li Q, Wang S, et al. The antioxidant mechanism of  
804 nitroxide TEMPO: scavenging with glutathionyl radicals. *RSC Adv*. 2015; 5: 63655–  
805 61.
- 806 40. Yu H, Ge Y, Wang Y, Lin C-T, Li J, Liu X, et al. A fused selenium-containing  
807 protein with both GPx and SOD activities. *Biochem Biophys Res Commun*. 2007;  
808 358: 873–8.
- 809 41. Liochev SI, Fridovich I. Copper- and zinc-containing superoxide dismutase can  
810 act as a superoxide reductase and a superoxide oxidase. *J Biol Chem*. 2000; 275:  
811 38482–5.
- 812 42. Wu T, Huang S, Yang H, Ye N, Tong L, Chen G, et al. Bimetal biomimetic  
813 engineering utilizing metal–organic frameworks for superoxide dismutase mimic.  
814 *ACS Mater Lett*. 2022; 4: 751–7.

- 815 43. Jalilov AS, Nilewski LG, Berka V, Zhang C, Yakovenko AA, Wu G, et al. Perylene  
816 diimide as a precise graphene-like superoxide dismutase mimetic. *ACS Nano*. 2017;  
817 11: 2024–32.
- 818 44. Liu X-W, Zi Y, Liu Y-E, Zhang Y-B, Xiang L-B, Hou M. Melatonin exerts protective  
819 effect on N2a cells under hypoxia conditions through Zip1/ERK pathway. *Neurosci*  
820 *Lett*. 2015; 595: 74–80.
- 821 45. Yang J, Zhang R, Zhao H, Qi H, Li J, Yang J-F, et al. Bioinspired copper single-  
822 atom nanozyme as a superoxide dismutase-like antioxidant for sepsis treatment.  
823 *Exploration*. 2022; 2: 20210267.
- 824 46. Tian Y, Ye Z, Wang X, Guan H, Liu W, Duan X, et al. MOF-818 nanozyme  
825 suppresses calcium oxalate kidney stones by alleviating oxidative stress and  
826 inflammatory injury. *Adv Healthc Mater*. 2024; 2401574.
- 827 47. Zhang Y, Gao W, Ma Y, Cheng L, Zhang L, Liu Q, et al. Integrating Pt  
828 nanoparticles with carbon nanodots to achieve robust cascade superoxide  
829 dismutase-catalase nanozyme for antioxidant therapy. *Nano Today*. 2023; 49:  
830 101768.
- 831 48. Wang C, Yang X, Dong C, Chai K, Ruan J, Shi S. Cu-related agents for cancer  
832 therapies. *Coord Chem Rev*. 2023; 487: 215156.
- 833 49. Zeng F, Tang L, Zhang Q, Shi C, Huang Z, Nijati S, et al. Coordinating the  
834 mechanisms of action of ferroptosis and the photothermal effect for cancer  
835 theranostics. *Angew Chem Int Ed*. 2022; 61: e202112925.
- 836 50. Aranda A, Sequedo L, Tolosa L, Quintas G, Burello E, Castell JV, et al. Dichloro-  
837 dihydro-fluorescein diacetate (DCFH-DA) assay: A quantitative method for oxidative  
838 stress assessment of nanoparticle-treated cells. *Toxicol In Vitro*. 2013; 27: 954–63.
- 839 51. Tang Z, Meng S, Yang X, Xiao Y, Wang W, Liu Y, et al. Neutrophil-mimetic, ROS  
840 responsive, and oxygen generating nanovesicles for targeted interventions of  
841 refractory rheumatoid arthritis. *Small*. 2024; 20: 2307379.
- 842 52. Kong J, Zou R, Chu R, Hu N, Liu J, Sun Y, et al. An ultras-small Cu/Cu<sub>2</sub>O  
843 nanoparticle-based diselenide-bridged nanoplatform mediating reactive oxygen  
844 species scavenging and neuronal membrane enhancement for targeted therapy of  
845 ischemic stroke. *ACS Nano*. 2024; 18: 4140–58.
- 846 53. Huang X, He D, Pan Z, Luo G, Deng J. Reactive-oxygen-species-scavenging  
847 nanomaterials for resolving inflammation. *Mater Today Bio*. 2021; 11: 100124.
- 848 54. Yang J, Liu H, Han S, Fu Z, Wang J, Chen Y, et al. Melatonin pretreatment  
849 alleviates renal ischemia-reperfusion injury by promoting autophagic flux via  
850 TLR4/MyD88/MEK/ERK/mTORC1 signaling. *FASEB J*. 2020; 34: 12324–37.
- 851 55. Li Y, Liang Q, Zhou L, Cao Y, Yang J, Li J, et al. An ROS-responsive artesunate  
852 prodrug nanosystem co-delivers dexamethasone for rheumatoid arthritis treatment  
853 through the HIF-1 $\alpha$ /NF- $\kappa$ B cascade regulation of ROS scavenging and macrophage  
854 repolarization. *Acta Biomater*. 2022; 152: 406–24.
- 855 56. Chen Q, Che C, Yang S, Ding P, Si M, Yang G. Anti-inflammatory effects of  
856 extracellular vesicles from *Morchella* on LPS-stimulated RAW264.7 cells via the  
857 ROS-mediated p38 MAPK signaling pathway. *Mol Cell Biochem*. 2023; 478: 317–27.

858 57. Liu X, Chen B, Chen J, Wang X, Dai X, Li Y, et al. A cardiac-targeted nanozyme  
859 interrupts the inflammation-free radical cycle in myocardial infarction. *Adv Mater.*  
860 2024; 36: 2308477.  
861